Deepak Kilari

1.8k citations

110 papers · 1.1k indexed · h-index 18

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
Cancer Research top 10%
- Cancer Genomics and Diagnostics

Papers in

Oncology 62
- Cancer Immunotherapy and Biomarkers 30
Pulmonary and Respiratory Medicine 72
- Prostate Cancer Treatment and Research 45
- Renal cell carcinoma treatment 22
- Prostate Cancer Diagnosis and Treatment 11

Co-authors: Kenneth A. Iczkowski William A. See Marja T. Nevalainen David T. Hoang Supriya G. Mohile Liang Wang Eric S. Kim Meijun Du
Journals: Journal of Clinical Oncology (46 papers)Annals of Oncology (13 papers)Clinical Genitourinary Cancer (5 papers)Oncotarget (3 papers)Frontiers in Oncology (3 papers)
Partner nations: United States Netherlands United Kingdom

In The Last Decade

Deepak Kilari

95 papers receiving 1.1k citations

Peers

Countries citing papers authored by Deepak Kilari

Since Specialization

Citations

This map shows the geographic impact of Deepak Kilari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepak Kilari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepak Kilari more than expected).

Fields of papers citing papers by Deepak Kilari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepak Kilari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepak Kilari. The network helps show where Deepak Kilari may publish in the future.

Co-authors

The 25 scholars most cited alongside Deepak Kilari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deepak Kilari Line = papers co-authored together Deepak Kilari links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer The Oncologist ·Rana R. McKay, Shayan Nazari, Andrew Elliott, Jennifer R. Ribeiro, Brent S. Rose, Pedro C. Barata, Deepak Kilari, Rohan Garje, Neeraj Agarwal, Norm D. Smith, Emmanuel S. Antonarakis, Aditya Bagrodia, Himisha Beltran	2025	0
2	5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies Communications Medicine ·Qianxia Li, Chiang‐Ching Huang, Shane Huang, Yijun Tian, Jinyong Huang, Amirreza Bitaraf, Xiaowei Dong, Marja T. Nevalainen, Manishkumar Patel, Jodie Wong, Jingsong Zhang, Brandon J. Manley, Jong Y. Park, Manish Kohli, Elizabeth Gore, Deepak Kilari, Liang Wang	2025	3
3	Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes European Urology Oncology ·Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, Ali T. Arafa, Laura Graham, Roman Gulati, Colin C. Pritchard, Bruce Montgomery, Michael C. Haffner, Peter S. Nelson, Evan Y. Yu, Jessica E. Hawley, Heather H. Cheng, George Mo, Delphine L. Chen, Emmanuel S. Antonarakis, Deepak Kilari, Thomas A. Hope, Amir Iravani, Michael T. Schweizer	2025	2
4	Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part. Journal of Clinical Oncology ·Ulka N. Vaishampayan, Randy F. Sweis, Deepak Kilari, Ahmad A. Tarhini, Justin F. Gainor, Minal Barve, Guru Sonpavde, Meredith McKean, Jae‐Hyun Park, Sunil Babu, Yawen Ju, Lan Liu, Susan A. Henry, Lu Gan, Timothy A. Yap	2024	1
5	Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial. Journal of Clinical Oncology ·Primo N. Lara, Stew Kroll, Jonathan Alexander Chatzkel, Deanna Teoh, T. Vincent, Deepak Kilari, Clara Hwang, Randy F. Sweis, Kiran Yalamanchili, Julio A. Peguero, Tianhong Li, Mamta Parikh	2024	1
6	1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC) Annals of Oncology ·Bibhusal Thapa, Nicole L. Henderson, S.T. Tagawa, Clara Hwang, Alexandra Sokolova, Mehmet Asım Bilen, P.M. Coelho Barata, Charles B. Nguyen, Archana Tripathi, Adanma Ayanambakkam, Laura Graham, Yousef Zakharia, V.S. Koshkin, Elisabeth I. Heath, Tanya B. Dorff, A.J. Armstrong, Rana R. McKay, Ajjai Alva, Michael T. Schweizer, Deepak Kilari	2024	0
7	Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends Cancer Management and Research ·Bicky Thapa, Navonil De Sarkar, Subhajit Giri, Komal Sharma, Mingee Kim, Deepak Kilari	2024	3
8	8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study ESMO Open ·Tanya Jindal, Changying Jiang, Omar Alhalabi, Charles B. Nguyen, Amanda Nizam, Arnab Basu, Yousef Zakharia, Mehmet Asım Bilen, James A. Brown, Matthew I. Milowsky, Deepak Kilari, Hamid Emamekhoo, Christopher Hoimes, Sumit Shah, Shilpa Gupta, Petros Grivas, Joaquim Bellmunt, Matthew T. Campbell, Ajjai Alva, Vadim S. Koshkin	2024	1
9	1600P Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC) Annals of Oncology ·Ulka N. Vaishampayan, Deepak Kilari, Tanya B. Dorff, J. Taylor, Jacqueline T. Brown, Alexandra Sokolova, Z. Reichert, P. Palmbos, Irene Tsung, Mariana Caram, Sarah Yentz, J. Alumkal, Bassel Nazha	2024	0
10	Non-clear cell renal cell carcinoma narrative review: where we are in 2024 Translational Cancer Research ·Michael Pierro, Alexander J. Gallan, Deepak Kilari	2024	1
11	1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1 Annals of Oncology ·Elena Castro, Douglas Laird, T. Dorff, Shuang G. Zhao, Inge M. van Oort, Donatello Gasparro, Fabio Calabrò, Sandro Pignata, Lajos Géczi, Philippe Barthélémy, Deepak Kilari, J.F. Hopkins, Hsiang‐Cheng Chen, Cynthia G. Healy, Jijumon Chelliserry, Giorgio V. Scagliotti, Johann S. de Bono, N. Mehra, Karim Fizazi	2023	2
12	Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma Clinical Genitourinary Cancer ·Akram Mesleh Shayeb, Hannah D. McManus, Danielle Urman, Chinmay Jani, Tian Zhang, Nazlı Dizman, Luís Meza, Akhilesh Sivakumar, Chun Loo Gan, Pedro C. Barata, Mehmet Asım Bilen, Xin Gao, Daniel Y.C. Heng, Sumanta K. Pal, Ravi Narra, Deepak Kilari, Marina D. Kaymakcalan, Bradley A. McGregor, Toni K. Choueiri, Rana R. McKay	2022	2
13	Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses The Oncologist ·Niven Mehra, Karim Fizazi, Johann S. de Bono, Philippe Barthélémy, Tanya B. Dorff, Adam Stirling, Jean‐Pascal Machiels, Davide Bimbatti, Deepak Kilari, Herlinde Dumez, Consuelo Buttigliero, Inge M. van Oort, Elena Castro, Hsiang-Chun Chen, Nicola Di Santo, Liza DeAnnuntis, Cynthia G. Healy, Giorgio V. Scagliotti	2022	11
14	Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development? Cancers ·Paul Beinhoff, Lavannya Sabharwal, Vindhya Udhane, Cristina Maranto, Peter S. LaViolette, Kenneth Jacobsohn, Susan Tsai, Kenneth A. Iczkowski, Liang Wang, William A. Hall, Scott M. Dehm, Deepak Kilari, Marja T. Nevalainen	2021	17
15	KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC) European Urology Open Science ·Ray McDermott, Jeremy Graff, Emmanuel S. Antonarakis, Christopher Hoimes, S.T. Tagawa, Clara Hwang, Deepak Kilari, Albert J. ten Tije, Aurelius Omlin, Ulka N. Vaishampayan, Andrew Elliott, Haiyan Wu, J. Kim, Charles Schloss, Johann S. de Bono	2020	2
16	771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer Annals of Oncology ·Vadim S. Koshkin, Yi Sun, Chelsea K. Osterman, Divya Natesan, Christopher Su, Emily Lemke, Ali Raza Khaki, Andrew R. Johnson, Xavier Owens, J.J. Park, Arnab Basu, P.M. Coelho Barata, Nancy B. Davis, Petros Grivas, Matthew I. Milowsky, Deepak Kilari, Ajjai Alva	2020	2
17	Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases ·Meijun Du, Yijun Tian, Winston Tan, Liewei Wang, Liguo Wang, Deepak Kilari, Chiang‐Ching Huang, Liang Wang, Manish Kohli	2020	18
18	Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors Molecular Cancer Therapeutics ·Vindhya Udhane, Cristina Maranto, David T. Hoang, Lei Gu, Andrew Erickson, Savita Devi, Pooja G. Talati, Anjishnu Banerjee, Kenneth A. Iczkowski, Kenneth Jacobsohn, William A. See, Tuomas Mirtti, Deepak Kilari, Marja T. Nevalainen	2019	21
19	Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm Clinical Genitourinary Cancer ·Ruben Raychaudhuri, Matthew J. Riese, Kathryn Bylow, John Burfeind, Alexander C. Mackinnon, Parag Tolat, Kenneth A. Iczkowski, Deepak Kilari	2017	15
20	Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting Journal of Geriatric Oncology ·Deepak Kilari, Enrique Soto‐Pérez‐de‐Celis, Supriya G. Mohile, Shabbir M.H. Alibhai, Carolyn J. Presley, Tanya M. Wildes, Heidi D. Klepin, Wendy Demark‐Wahnefried, A. Jatoi, Robert G. Harrison, Elizabeth Won, Karen M. Mustian	2016	56

About Deepak Kilari

Deepak Kilari is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Geriatrics and Gerontology and Surgery, having authored 110 papers that have together received 1.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (45 papers), Bladder and Urothelial Cancer Treatments (36 papers), Cancer Immunotherapy and Biomarkers (30 papers), Renal cell carcinoma treatment (22 papers), Cancer Genomics and Diagnostics (15 papers), Urinary and Genital Oncology Studies (12 papers), Prostate Cancer Diagnosis and Treatment (11 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). The work is most often cited by research in Oncology (558 citations), Cancer Research (281 citations), Geriatrics and Gerontology (56 citations), Pulmonary and Respiratory Medicine (466 citations) and Immunology (126 citations). Deepak Kilari has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Kenneth A. Iczkowski, William A. See, Marja T. Nevalainen, David T. Hoang, Supriya G. Mohile, Liang Wang, Eric S. Kim, Meijun Du, Manish Kohli and Chiang‐Ching Huang. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Genitourinary Cancer, Oncotarget and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact